FDA panel says data does not support lower heart risk of naproxen
Feb 11 (Reuters) - An advisory panel to the U.S. Food and Drug Administration voted on Tuesday that there is not enough evidence to show conclusively that the painkiller naproxen carries a lower cardiac risk than other popular products.
The panel voted 16-9 that a retrospective review of clinical data does not prove that naproxen, a drug contained in the prescription product Naprosyn and over-the-counter Aleve, carries less cardiovascular risk than rival products such as ibuprofen.
Naprosyn is made by Roche Holding, and Aleve is a product of Bayer AG.
- Investigators look for motive in Malaysia plane disappearance |
- Police make third arrest in murder of Colorado socialite
- Malaysian PM says lost airliner was diverted deliberately |
- Indian Ocean poses daunting challenge in search for missing Malaysia plane
- Malaysia PM says lost plane's movements indicate a deliberate act